Novel missense mutation in the CASR gene in a Chinese family with familial hypocalciuric hypercalcemia.

Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.
Clinica Chimica Acta (Impact Factor: 2.76). 11/2005; 360(1-2):167-72. DOI: 10.1016/j.cccn.2005.04.026
Source: PubMed

ABSTRACT Familial hypocalciuric hypercalcemia (FHH) is an autosomal dominant disorder characterized by asymptomatic and non-progressive hypercalcemia resulting from loss-of-function mutations of the CASR (calcium-sensing receptor) gene located on chromosome 3, or from mutations in two mapped but unidentified genes located on chromosome 19.
We report a middle-aged woman incidentally found to have FHH. To determine the molecular basis of FHH in this Chinese family, we performed direct DNA sequencing of the CASR gene of the proband.
We found that the proband is heterozygous for a novel missense mutation P798T, confirming the diagnosis of FHH. Family screening showed that all of the offspring with biochemical features of FHH have the P798T mutation. The mutation, P798T, is located in the third intracellular loop of the CASR, possibly affecting the downstream calcium sensing pathway and therefore inactivating the receptor function.
The molecular basis of FHH in a Chinese family was established. The developed mutation detection assay provides a reliable method for identifying FHH carriers.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The calcium-sensing receptor (CASR) is expressed in parathyroid hormone (PTH)-secreting cells of the parathyroid gland and cells lining the renal tubule. The activated CASR modulates intracellular signaling pathways altering PTH secretion and renal cation and water handling. Inherited abnormalities of the CASR gene give rise to a variety of disorders of mineral ion homeostasis. Heterozygous loss-of-function mutations cause familial (benign) hypocalciuric hypercalcemia (FHH) in which the lifelong mild hypercalcemia is generally asymptomatic. Homozygous inactivating mutations give rise to neonatal severe hyperparathyroidism (NSHPT) with extreme hypercalcemia and marked skeletal changes. Heterozygous activating mutations of the CASR cause autosomal dominant hypocalcemia (ADH) that may be asymptomatic or present with seizures in the neonatal period or childhood or later in life. Phenocopies of FHH or ADH are due to circulating CASR inactivating or activating autoantibodies, respectively. The CASR is the target of small molecule allosteric modifiers, either activators, calcimimetics, or inhibitors, calcilytics.
    Progress in molecular biology and translational science 01/2009; 89:31-95. DOI:10.1016/S1877-1173(09)89003-0 · 3.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glycine sodium nitrite (GSNi) having non linear optical efficiency more than KDP crystal has been obtained from solutions by slow cooling technique. The crystals are found to be chemically and thermally stable with orthorhombic unit cell. The presence of wide transparency window in UV–Visible region makes GSNi suitable for opto-electronic device applications. It has second harmonic generation efficiency of 1.273 times that of standard KDP crystal. GSNi crystal belongs to soft category of materials with work hardening index of 2.33. Crystals introduced in timer circuit gave a stable output with the capacitance value of 236pF. I–V characteristic indicates a safe operating range of 300V/cm. GSNi is seen to behave as a normal dielectric with applied frequency and crystals exposed to light exhibit negative LDR characteristic which is attributable to space charge formation.
    Optics Communications 02/2012; DOI:10.1016/j.optcom.2011.09.023 · 1.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the discovery of the first rhodopsin mutation that causes retinitis pigmentosa in 1990, significant progresses have been made in elucidating the pathophysiology of diseases caused by inactivating mutations of G protein-coupled receptors (GPCRs). This review aims to compile the compelling evidence accumulated during the past 15 years demonstrating the etiologies of more than a dozen diseases caused by inactivating GPCR mutations. A generalized classification scheme, based on the life cycle of GPCRs, is proposed. Insights gained through detailed studies of these naturally occurring mutations into the structure-function relationship of these receptors are reviewed. Therapeutic approaches directed against the different classes of mutants are being developed. Since intracellular retention emerges as the most common defect, recent progresses aimed at correcting this defect through membrane permeable pharmacological chaperones are highlighted.
    Pharmacology [?] Therapeutics 10/2006; 111(3):949-73. DOI:10.1016/j.pharmthera.2006.02.008 · 7.75 Impact Factor